Drugs that trigger inflammatory cancer cell death to boost immunotherapy
Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
Trying to make 'cold' tumors more visible to the immune system by using small drugs that cause a highly inflammatory form of cancer cell death so more people benefit from immunotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11254896 on NIH RePORTER |
What this research studies
This project aims to create small drug compounds that activate a protein called ZBP1 inside tumor cells to induce 'nuclear necroptosis,' a form of cell death that releases strongly inflammatory nuclear material. In lab-grown cells and animal tumor models, the team will test whether inducing nuclear necroptosis turns immunologically 'cold' tumors into 'hot' tumors that attract immune cells and respond better to checkpoint inhibitors. The researchers plan to design molecules that mimic the Z-RNA/Z-DNA signals that switch on ZBP1 and measure immune responses in the tumor microenvironment. The work is preclinical with the goal of identifying candidate drugs for future clinical testing in people with resistant cancers.
Who could benefit from this research
Good fit: People with solid tumors that are poorly infiltrated by immune cells or who have not responded to immune checkpoint therapies would be the most likely candidates for future trials based on this work.
Not a fit: Patients whose cancers already respond well to existing immunotherapies, certain blood cancers, or tumors lacking the ZBP1 pathway are less likely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could make cancers that now resist immunotherapy respond by provoking a stronger immune attack inside the tumor.
How similar studies have performed: Basic lab studies have shown necroptosis can enhance anti-tumor immunity, but using small molecules to trigger nuclear ZBP1-driven necroptosis is a new approach not yet tested in humans.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Balachandran, Siddharth — Research Inst of Fox Chase Can Ctr
- Study coordinator: Balachandran, Siddharth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.